🔔 Leadership Alert
Rajeev Kumar Sinha resigns as Global Chief Manufacturing Officer of Cipla effective April 2, 2025.
Cipla Analyst Rating
based on 36 analysts
62.16%
Buy
21.62%
Hold
16.22%
Sell
Based on 36 analysts offering long term price targets for Cipla. An average target of ₹1640.97
Source: S&P Global Market Intelligence
Cipla Share analysis
Cipla price forecast by 36 analysts
Upside of13.08%
High
₹1960
Target
₹1640.97
Low
₹1204
Cipla target price ₹1640.97, a slight upside of 13.08% compared to current price of ₹1411.4. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla revenue growth forecast
Expected growth rate Q1, FY2027:24.51%
Forecast
Actual
Including amortisation and stock based compensations
Cipla EPS growth forecast
EPS estimate Q1, FY2027:29.21%
Forecast
Actual
Source: S&P Global Market Intelligence
Cipla Performance
Day's Low
Day's High
₹1,408Day's Price Range₹1,45152 Week's Low
52 Week's High
₹1,31252-Week Price Range₹1,702.05
| Returns % | |
| 1 Month Return | -1.67 % |
| 3 Month Return | -2.76 % |
| 1 Year Return | + 2.38 % |
| Market Stats | |
| Previous Close | ₹1,451.15 |
| Open | ₹1,445.25 |
| Volume | 16.15L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,17,196.91Cr |
Cipla Key Statistics
| P/E Ratio | 26.18 |
| PEG Ratio | 2.07 |
| Market Cap | ₹1,17,196.91 Cr |
| P/B Ratio | 4.31 |
| EPS | 51.47 |
| Dividend Yield | 0.87 |
| Sector | Pharmaceuticals |
| ROE | 15.5 |
Cipla Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,17,196.91 Cr | 43.25% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,55,324.34 Cr | 41.25% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,10,455.17 Cr | 44.09% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹47,699.84 Cr | 7% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹26,730.14 Cr | -2.17% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Cipla
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Share Price: ₹1411.40 per share as on 24 Jan, 2025 04:01 PM
Market Capitalisation: ₹1,17,196.91Cr as of today
Revenue: ₹6,961.22Cr as on September 2024 (Q3 24)
Net Profit: ₹1,306.02Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
What's happening today
Today's Timeline - Invalid Date
03:52 AM
-Rajeev Kumar Sinha resigns as Global Chief Manufacturing Officer of Cipla, effective April 2, 2025.
12:20 PM
-Cipla's Q3 preview indicates weak US sales may cap revenue growth, but steady India business offers support.
01:04 PM
-Analysts predict low-double digit EPS growth for Cipla, supported by cash flow despite challenges in US sales.
Key events for Cipla Ltd
Cipla Faces Challenges Amid Leadership Change and Sales Pressure - 24 Jan, 2025
Cipla's Global Chief Manufacturing Officer resigns, while Q3 results show weak US sales impacting revenue growth. Analysts expect low-double digit EPS growth despite challenges.Cipla Receives USFDA Observation for Goa Facility - 20 Jan, 2025
Cipla Ltd announced that its Goa facility, Medispray Laboratories, received one observation from the USFDA following an inspection. The company is committed to addressing the observation promptly.Cipla Tax Demand Reduced Significantly - 15 Jan, 2025
Cipla Limited's tax demand for Assessment Year 2020-21 has been reduced from ₹312.96 crores to ₹98.70 crores, lowering the total demand from AY 2015-16 to AY 2022-23 to ₹559.18 crores.Cipla Launches Asthma Screening Mobile App - 06 Jan, 2025
Cipla has launched the CipAir mobile application for asthma screening in India, aiming to improve early diagnosis and management of asthma, which affects millions.Cipla Receives Buy Recommendation Amid Price Rise - 30 Dec, 2024
Cipla Ltd has been recommended as a buy by Axis Securities with a target price of Rs 1,735. The stock is currently up 1.09% at Rs 1523, reflecting a 21.74% increase over the past year, outperforming both NIFTY and the Nifty Pharma index.Analyst Recommends Buy for Cipla Stock - 27 Dec, 2024
Analyst Shrikant Chouhan from Kotak Securities suggests buying Cipla Ltd shares with a target price of ₹1,550-1,565 and a stop loss at ₹1,465.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 6.41K Cr → 7.24K Cr (in ₹), with an average increase of 5.9% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 939.04 Cr → 1.30K Cr (in ₹), with an average increase of 14.9% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 27.77% to 28.74% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 103.2% return, outperforming this stock by 47.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 30.86% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 46.6% return, outperforming this stock by 37.0%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 16.30% to 16.08% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, CIPLA stock has moved down by -0.6%
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 17.59% to 17.44% in Sep 2024 quarter
News
Dr Reddy’s, Zydus, Cipla, Sun: Sustaining Low-Double Digit EPS Growth
companies like Dr Reddys, Zydus Cipla, Sun, can sustain a low-double digit EPS growth over the medium term. Low-double digit is 11%, 12%, 13%, for companies which are offering 12% to 13% earnings growth on a sustainable basis and given the cash flow profile of these companies, these could trade anywhere between 25 and 35 times one year forward depending on the market and current market valuations. The generic Revlimid opportunity was a real once-in-a-lifetime sort of opportunity that the Indian pharma companies got back home, and not just Cipla.24 Jan, 2025 01:04 PMCipla Q3 Preview: Weak US Sales to Cap Revenue Growth
Cipla will release its Q3 results on January 28. While a weakness in the drugmakers US sales is expected to cap its revenue growth in the fiscal third quarter, steady domestic growth is likely to offer some relief. According to a Moneycontrol poll of 10 brokerages, Ciplas net profit is estimated to grow 16 percent at Rs 1,225 crore, up from Rs 1,056 crore reported in the same period last fiscal. The revenue is likely to see a marginal 5 percent increase to Rs 6,925 crore in the December quarter as compared to Rs 6,603 crore in the corresponding quarter last year. However, operational performance is expected to witness a blip due to lower US sales impacting the mix. As per the forecasts collated by Moneycontrol, Ciplas EBITDA margin may see a 20 basis points squeeze on-year to 26.1 percent in Q3. The drugmakers US sales is likely to remain under pressure in an otherwise seasonally strong quarter. Lower US sales: Ciplas US sales in Q3 are likely to decline on-year due to price erosion and temporary lower off-take of tumor drug Lanreotide. The management had informed about supply disruptions in Lanreotide last quarter, which was expected to normalise around Q4. Accordingly, US sales below $220 million for Q3 was guided. Margin performance: Weak US sales in the quarter may bring a slight drag on the companys margin performance due to its impact on the product mix. Despite that, brokerages remain confident of the company meeting its margin guidance of 24.5-25.5 percent for FY25, supported by lower raw material costs and operating leverage. India sales: Nomura anticipates a 7 percent on year rise in India sales for Cipla. The on year growth is adversely impacted due to weak seasonal demand for acute therapies, particularly in the respiratory segment, and the high base of last year, Nomura said. However, the firm also expects a positive impact from the distribution agreement with Sanofi for CNS (Central Nervous System) products to offer some comfort. In Nomuras view, the sales from this agreement should have a positive 1.5 percent impact on year-on-year domestic growth rates. Analysts will closely monitor updates on the approval and launch timeline of products from Ciplas Goa facility following its regulatory clearance. In particular, investors will remain focused on the launch timeline of the blockbuster oncology drug Abraxane, which is slated to be filed and manufactured from the Goa facility. Aside from that, Ciplas outlook on the recovery of Lanreotide sales from Q4 will also be on the radar. The drug is currently a major revenue opportunity for Cipla.24 Jan, 2025 12:20 PMStocks to Watch Today: Key Earnings and Corporate Developments
Rajeev Kumar Sinha has resigned as Global Chief Manufacturing Officer of the pharmaceutical company due to personal reasons, effective April 2, 2025.24 Jan, 2025 03:52 AMCipla Financials
Index Inclusions
Cipla Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 30.86% | ||
| Foreign Institutions | 28.74% | 3.49 | |
| Mutual Funds | 17.44% | ||
| Retail Investors | 16.08% | ||
| Others | 6.89% |
Cipla Key Indicators
Cipla Valuation
Cipla in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (26.18x)
January 23, 2025
Industry (54.94x)
January 23, 2025
Highest (42.80x)
January 23, 2018
Cipla Earnings and Dividends
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 15.18% since last year same period to ₹1,302.53Cr in the Q2 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 10.61% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.52%.
Read More about Dividends
Cipla Technicals Summary
Bearish
Neutral
Bullish
Cipla Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Cipla Ltd
Cipla Ltd share price today stands at ₹1411.4, Open. ₹1445.25 ; Previous Close. ₹1451.15 ; High. ₹1451 ; Low. ₹1408 ; 52 Week High. ₹1702.05 ; 52 Week Low: ₹1312.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Cipla Ltd shares.
Cipla Ltd is listed on NSE
Cipla Ltd is listed on BSE
- Today’s highest price of Cipla Ltd is ₹1451.
- Today’s lowest price of Cipla Ltd is ₹1408.
PE Ratio of Cipla Ltd is 26.18
PE ratio = Cipla Ltd Market price per share / Cipla Ltd Earnings per share
Today’s traded volume of Cipla Ltd(CIPLA) is 16.15L.
Today’s market capitalisation of Cipla Ltd(CIPLA) is ₹117196.91Cr.
| Cipla Ltd(CIPLA | Price |
|---|---|
52 Week High | ₹1702.05 |
52 Week Low | ₹1312 |
Cipla Ltd(CIPLA) share price is ₹1411.4. It is down -17.08% from its 52 Week High price of ₹1702.05
Cipla Ltd(CIPLA) share price is ₹1411.4. It is up 7.58% from its 52 Week Low price of ₹1312
| Cipla Ltd(CIPLA | Returns |
|---|---|
1 Day Returns | -39.75% |
1 Month Returns | -1.67% |
3 Month Returns | -2.76% |
1 Year Returns | 2.38% |